STIMULATION OF HUMAN CORONARY ANGIOGENESIS WITH BASIC FGF
用碱性 FGF 刺激人冠状动脉血管生成
基本信息
- 批准号:6450726
- 负责人:
- 金额:$ 27.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-04-01 至 2002-03-31
- 项目状态:已结题
- 来源:
- 关键词:angiogenesis cardiovascular disorder chemotherapy cardiovascular disorder diagnosis clinical research coronary vessels drug delivery systems fibroblast growth factor human subject miniature swine myocardial ischemia /hypoxia noninvasive diagnosis nuclear magnetic resonance spectroscopy protein tyrosine kinase receptor binding
项目摘要
The purpose of the present study is to the clinical efficacy of basic
fibroblast growth factors (bFGF) in coronary angiogenesis in the setting
of chronic myocardial ischemia. Ischemic coronary disease is the leading
cause of morbidity and mortality in the Western world. Most available
therapeutic approaches aim either at relieving symptoms by reducing
myocardial oxygen demand, preventing further disease progression by
modifying risk factors, restoring flow to a localized segment of the
arterial tree (angioplasty) or bypassing obstruction (bypass surgery).
However, no attempts have been made to restore blood supply to the
myocardium by providing new venues for blood flow. Therapeutic
angiogenesis may serve this goal. Angiogenesis is a complex process
involving endothelial and smooth muscle cell proliferation and migration,
formation of new capillaries, breakdown of existing extracellular matrix
and formation of a new one. Relatively little is know regarding
physiological importance and therapeutic potential of this process in
chronic myocardial ischemia and molecular cellular events involved in its
regulation are poorly understood. Preliminary investigation using animal
models have shown that bFGF can be used to stimulate physiologically
significant angiogenesis in myocardial ischemia. However, to date there
has been no experience with the use of this growth factor in patients. The
present study, therefore, will examine 3 Specific Aims: I. Angiogenic
efficiency of bFGF chronic myocardial ischemia; II. Role of magnetic
resonance imaging in noninvasive assessment of coronary angiogenesis; III.
valuation of other tyrosine kinase ligands in stimulation of angiogenesis
in chronic myocardial ischemia.
本研究的目的是为了了解其临床疗效
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Simons其他文献
Michael Simons的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Simons', 18)}}的其他基金
Ischemia/Reperfusion injury and Myocardial edema
缺血/再灌注损伤和心肌水肿
- 批准号:
10718260 - 财政年份:2023
- 资助金额:
$ 27.43万 - 项目类别:
Vascular smooth muscle cell heterogeneity and disease
血管平滑肌细胞异质性与疾病
- 批准号:
10356855 - 财政年份:2021
- 资助金额:
$ 27.43万 - 项目类别:
Vascular smooth muscle cell heterogeneity and disease
血管平滑肌细胞异质性与疾病
- 批准号:
10559596 - 财政年份:2021
- 资助金额:
$ 27.43万 - 项目类别: